Trending...
- "Street Fighterâ„¢ 6" Panel Announced for December 2nd at Los Angeles Comic Con; The Music of Street Fighter 6: A Special Look at the Video Game
- Allotex Announces New Investor and Expansion of Production Facilities USA - English USA - English
- Boston: Traffic Advisory for December 1- 3, 2023
Download
The current standard of care options for rebuilding deficient jawbone includes a variety of materials that require membranes and time consuming fixation devices. These products do not predictably maintain ridge volume which requires surgeons to undergo re-grafting in over 30% of clinical cases. TETRANITE eliminates the use of membranes and other fixation devices, when compared to the standard of care. Furthermore, TETRANITE resorbs fully while maintaining predictable ridge volume throughout the bone regeneration process. (Graphic: Business Wire)
LOWELL, Mass.--(BUSINESS WIRE)--RevBio, Inc., announced that it has been awarded a $2 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health (NIH). This funding (1R44DE032564-01) will allow the company to complete the pre-clinical research necessary to advance this product into the clinical stage of development.
More on Boston Chron
"We have optimized the TETRANITE bone adhesive technology to accelerate the substitution of the biomaterial with new bone through key engineering and manufacturing innovations which significantly increase the porosity of the material," said Rahul Jadia, PhD, RevBio's R&D Manager of Technology Development, who has led the development of this novel adhesive bone scaffold product. "This grant will allow the company to conduct a pivotal animal study necessary to demonstrate safety and efficacy of the product and to file an Investigational Device Exemption (IDE) application with the FDA next year to start a clinical trial."
Research shows that 44% of all patients who receive a dental implant have a missing tooth when they start treatment with varying degrees of bone loss depending on how long the tooth had been missing. These patients must undergo a ridge augmentation procedure in which various bone graft materials are placed using additional fixation and containment devices to protect the graft during the healing process. These procedures increase the width and height of the residual jawbone to replace atrophied bone so that a dental implant can be successfully placed. In over 30% of these cases, however, existing bone graft materials fail to achieve the desired clinical results, and another bone graft procedure must be conducted, increasing the overall time and cost of treatment. This product compliments RevBio's existing clinical program to treat the larger population of patients who need an immediate dental implant following tooth extraction.
This grant significantly enhances prior funding awarded to RevBio by the Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center which is a research consortium funded by the National Institute of Dental and Cranial Research (U24-DE029462) to improve the translation of promising tissue engineering and regenerative medicine technologies for dental, oral, and craniofacial clinical practice.
More on Boston Chron
"This enhanced adhesive formulation of TETRANITE resorbs and is replaced by bone on a timescale similar to existing graft materials but, unlike those existing materials, it does not require ancillary containment devices like membranes or meshes or fixation aids like tacks and screws," said Joseph P. Fiorellini, DMD, DMSc, Professor at the University of Pennsylvania School of Dental Medicine and Chair of RevBio's Dental Scientific Advisory Board. "The clinical use of this material will reduce the time and complexity of ridge augmentation procedures and likely lead to more consistent results with better volume maintenance of these grafts."
About RevBio, Inc.
RevBio, Inc., is a clinical stage medical device company engaged in the development and commercialization of a patented, synthetic, injectable, self-setting, and osteoconductive bone adhesive biomaterial called TETRANITE®. The company is initially developing this technology for use in the dental, cranial, and broader orthopaedic markets as well as applications in the animal health market. RevBio's TETRANITE technology is not yet approved for commercial use.
Contacts
Michael Tiedemann
mtiedemann@revbio.com
Release Summary
RevBio is Awarded a $2 Million Grant to Advance the Development of its Novel Dental Adhesive Bone Scaffold Product
0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>
#Hashtags
Social Media Profiles
Contacts
Michael Tiedemann
mtiedemann@revbio.com
The current standard of care options for rebuilding deficient jawbone includes a variety of materials that require membranes and time consuming fixation devices. These products do not predictably maintain ridge volume which requires surgeons to undergo re-grafting in over 30% of clinical cases. TETRANITE eliminates the use of membranes and other fixation devices, when compared to the standard of care. Furthermore, TETRANITE resorbs fully while maintaining predictable ridge volume throughout the bone regeneration process. (Graphic: Business Wire)
- The current standard of care options for rebuilding deficient jawbone includes a variety of materials that require membranes and time consuming fixation devices. These products do not predictably maintain ridge volume which requires surgeons to undergo re-grafting in over 30% of clinical cases. TETRANITE eliminates the use of membranes and other fixation devices, when compared to the standard of care. Furthermore, TETRANITE resorbs fully while maintaining predictable ridge volume throughout the bone regeneration process. (Graphic: Business Wire)
LOWELL, Mass.--(BUSINESS WIRE)--RevBio, Inc., announced that it has been awarded a $2 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health (NIH). This funding (1R44DE032564-01) will allow the company to complete the pre-clinical research necessary to advance this product into the clinical stage of development.
More on Boston Chron
- Massachusetts: Healey-Driscoll Administration Holds First Regional Cabinet Meeting in Amherst
- Empowering Voices: Houston's Black Authors Illuminate the Blockchain World with 'Chain Reaction'
- Unlocking the Magic of Miami Beach
- Introducing Scuba Diving Industry Magazine
- Five-year Contract Ratified by Boston Police Patrolmen's Association
"We have optimized the TETRANITE bone adhesive technology to accelerate the substitution of the biomaterial with new bone through key engineering and manufacturing innovations which significantly increase the porosity of the material," said Rahul Jadia, PhD, RevBio's R&D Manager of Technology Development, who has led the development of this novel adhesive bone scaffold product. "This grant will allow the company to conduct a pivotal animal study necessary to demonstrate safety and efficacy of the product and to file an Investigational Device Exemption (IDE) application with the FDA next year to start a clinical trial."
Research shows that 44% of all patients who receive a dental implant have a missing tooth when they start treatment with varying degrees of bone loss depending on how long the tooth had been missing. These patients must undergo a ridge augmentation procedure in which various bone graft materials are placed using additional fixation and containment devices to protect the graft during the healing process. These procedures increase the width and height of the residual jawbone to replace atrophied bone so that a dental implant can be successfully placed. In over 30% of these cases, however, existing bone graft materials fail to achieve the desired clinical results, and another bone graft procedure must be conducted, increasing the overall time and cost of treatment. This product compliments RevBio's existing clinical program to treat the larger population of patients who need an immediate dental implant following tooth extraction.
This grant significantly enhances prior funding awarded to RevBio by the Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center which is a research consortium funded by the National Institute of Dental and Cranial Research (U24-DE029462) to improve the translation of promising tissue engineering and regenerative medicine technologies for dental, oral, and craniofacial clinical practice.
More on Boston Chron
- The Five Pillars of Success Pillar One Strengths Outlined by Rosann Santos CPC
- Pitch Black Appoints New Chief People Officer
- SmartBear Wins Winter 2023 Digital Innovator Award from Intellyx
- Mayor Michelle Wu announces five-year contract ratified by Boston Police Patrolmen's Association, codifying operational reforms and fair compensation
- Tanisha Deleon Named Deputy Director of Youth Options Unlimited Boston
"This enhanced adhesive formulation of TETRANITE resorbs and is replaced by bone on a timescale similar to existing graft materials but, unlike those existing materials, it does not require ancillary containment devices like membranes or meshes or fixation aids like tacks and screws," said Joseph P. Fiorellini, DMD, DMSc, Professor at the University of Pennsylvania School of Dental Medicine and Chair of RevBio's Dental Scientific Advisory Board. "The clinical use of this material will reduce the time and complexity of ridge augmentation procedures and likely lead to more consistent results with better volume maintenance of these grafts."
About RevBio, Inc.
RevBio, Inc., is a clinical stage medical device company engaged in the development and commercialization of a patented, synthetic, injectable, self-setting, and osteoconductive bone adhesive biomaterial called TETRANITE®. The company is initially developing this technology for use in the dental, cranial, and broader orthopaedic markets as well as applications in the animal health market. RevBio's TETRANITE technology is not yet approved for commercial use.
Contacts
Michael Tiedemann
mtiedemann@revbio.com
Release Summary
RevBio is Awarded a $2 Million Grant to Advance the Development of its Novel Dental Adhesive Bone Scaffold Product
0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>
#Hashtags
- #TETRANITE (https://twitter.com/hashtag/TETRANITE?src=hash)
- #DentalBoneGrafting (https://twitter.com/hashtag/DentalBoneGrafting?src=hash)
- #BoneScaffold (https://twitter.com/hashtag/BoneScaffold?src=hash)
- #clinicalstage (https://twitter.com/hashtag/clinicalstage?src=hash)
- #regeneration (https://twitter.com/hashtag/regeneration?src=hash)
- #investment (https://twitter.com/hashtag/investment?src=hash)
- #biomaterials (https://twitter.com/hashtag/biomaterials?src=hash)
- #dental (https://twitter.com/hashtag/dental?src=hash)
- #BoneAdhesive (https://twitter.com/hashtag/BoneAdhesive?src=hash)
- #innovation (https://twitter.com/hashtag/innovation?src=hash)
Social Media Profiles
- RevBio on Facebook (https://www.facebook.com/REVBIOINC/)
- RevBio on Twitter (https://twitter.com/revbio_?lang=en)
- RevBio on LinkedIn (https://www.linkedin.com/company/revbio-inc/)
- RevBio on Instagram (https://www.instagram.com/revbio_/?hl=en)
- RevBio on Vimeo (https://vimeo.com/revbio)
Contacts
Michael Tiedemann
mtiedemann@revbio.com
Filed Under: Business
0 Comments
Latest on Boston Chron
- Revolutionizing FEC Chain Stores with Our Cutting-Edge Ordering& Warehousing System
- Boston: Barbados Celebrates 57 Years
- Boston: Honoring National Survivors of Homicide Awareness Month
- State Street to Further Consolidate Operating Model in India
- Media Personality Cyrus Webb celebrates 20 years and over 12,000 guests on Conversations LIVE radio show
- Revolutionizing Interaction: Surface Computing's $257.0 Billion Journey by 2028 - Insights from BCC Research
- Panovolo for macOS is now available
- Lumena, A New Luxury Oceanfront Condominium Takes Flight on Florida's Space Coast
- Dogs at the Dentist: How an unlikely partnership is helping treat dental anxiety
- Amundi US Declares Monthly Distributions for Pioneer Closed-End Funds
- SSV Network selects Randamu for Distributed Key Generation (DKG) Grant Award
- Lawmato relaunches its virtual consultation app with enhanced features
- Boston: Traffic Advisory for December 1- 3, 2023
- MiBOXER Is Exhibiting At Hong Kong International Autumn Lighting Fair
- Beck Properties Group, eXp Realty Expands Service in Southeast Indiana
- Massachusetts: Healey-Driscoll Administration Launches Statewide Coastal Resiliency Strategy
- Stonely Unleashes Innovative Platform for Homeowners: Design and Order Kitchen Countertops Online with Ease!
- One Million Pages Read in the First Year !!
- Kingston NY-Based Ryan & Ryan Kicks Off its 65th Anniversary Dec. 6 by Underwriting a Chamber of Commerce Mixer Saluting RUPCO
- The Best Dyson Deals for Cyber Week at Best Buy (2023): Best Cordless Vacuum, Air Purifier, Supersonic Hair Dryer & More Sales Shared by Consumer Articles